Breakthrough during Interferon therapy for chronic hepatitis C. Overview on the diagnosis, possible aetiology and recommendations for management

Italian Journal of Gastroenterology and Hepatology

Volumn 30, Issue 3, 1998, Pages 333-337

  Colloredo, G ^a   Roffi, L ^b   Bellati, G ^b  

^a SAN GERARDO HOSPITAL   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Breakthrough; Chronic hepatitis c; Ifn therapy

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; INTERFERON ANTIBODY; INTERFERON RECEPTOR; NEUTRALIZING ANTIBODY;

AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS; HEPATITIS C; REVIEW;

ANTIBODY FORMATION; ANTIVIRAL AGENTS; DOWN-REGULATION; DRUG RESISTANCE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; PROGNOSIS; RECEPTORS, INTERFERON; TRANSAMINASES; TREATMENT FAILURE; VIRAL LOAD;

EID: 0031829608     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Lindsay K.L. Therapy of hepatitis C: overview. Hepatology 1997;26(Suppl. 1):71S-77S.
2. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alpha therapy for chronic hepatitis C: a randomised double-blind placebocontrolled trial. N Engl J Med 1989;321:1506-10.
3. Pawlotsky JM, Bastie A, Roudot-Thoraval F, Lebon P, Darthuy F, et al. Breakthrough during interferon therapy for chronic hepatitis C: evolution of HCV replication and evaluation of associated factors. IX° ISVHLD, Rome 1996; p. 27, Abstract 90.
4. Shindo M, Di Bisceglie AM, Hoofnagle JH. Acute exacerbation of liver disease during Interferon alfa therapy for chronic hepatitis C. Gastroenterology 1992;102:1406-8.
5. Garcia-Buey L, Garcla-Monzön C, Rodriguez S, Borque MJ. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995;108:1770-7.
6. Diodati G, Bonetti P, Noventa F, Casarin C, Rugge M, Scaccabarozzi S, et al. Treatment of chronic hepatitis C with recombinant human Interferon alpha-2a: results of a randomised controlled clinical trial. Hepatology 1994;19:l-5.
7. Davis GL, Baiart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomised, controlled trial. N Engl J Med 1989;321:1501-6.
8. Lebovics E, Lantin J, Chaurushia G, Dworkin BM, Casellas A, Rosenthal WS. The breakthrough phenomenon during alfa-interferon therapy of chronic hepatitis C: incidence, management and outcome. Am J Gastroenterol 1995;90:951-4,
9. Bellati G, Colloredo G, Roffi L, D'Aquino M, Bonino F, Ideo G, and Chonic Hepatitis Study Group. Prevalence of Breakthrough in chronic hepatitis C patients undergoing antiviral therapy: role of type and schedule of Interferon. J Hepatol 1997;26:449-50.
10. Milella M, Antonelli G, Santantonio T, Current! M, Monno L, Mariano N, et al. Neutralising antibodies to recombinant alphainterferon and response to therapy in chronic hepatitis C virus infection. Liver 1993;13:146-50.
11. Steis RG, Smith JW, Urba WJ, Clark JW, Itri LM, Evans LM, et al. Resistance to recombinant interferon alpha-2a in hairy cell leukaemia associated with neutralising anti-interferon antibodies. N Engl J Med 1988;318:1409-13.
12. Von Wussow P, Freund M, Block B, Dietrich H, Poliwoda H, Deicher H. Clinical significance of anti-IFN alpha antibodies titres during interferon therapy. Lancet 1987;2:635-6.
13. Catani L, Zauli G, Gianni L, Vianelli N, Mattioli Belmonte M, Cascione ML, et al. The antiproliferative effect of lymphoblastoid interferon is not blocked by interferon alpha-2A neutralising antibodies. J Interferon Res 1989;9:S294,Abstract B7-5.
14. Von Wussow P, Jakschies D, Freund M, Heimann H, Brockhaus F. The treatment of anti IFN alpha 2 antibody positive CML patients with natural interferon alpha. J Interferon Res 1989;9:S 113.
15. Porres JC, Carreno V, Ruiz M, Marron JA, Bartolomé J. Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon. J Hepatol 1989;8:351-7.
16. Lok AS-F, Lai C-L, Leung EK-Y. Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology 1990;12:1266-70.
17. Roffi L, Colloredo Mels G, Antonelli G, Bellati G, Panizzuti F, et al. Breakthrough during recombinant alfa-Interferon therapy in patients with chronic hepatitis C virus infection: prevalence, aetiology and management. Hepatology 1995;21:645-9.
18. Bonetti P, Chemello L, Alberti A. Anti-Interferon antibodies during interferon therapy for chronic hepatitis C. J Hepatol 1994;21:135(letter).
19. Antonelli G, Giannelli G, Current! M, Simeoni E, Del Vecchio S, Maggi F, et al. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant-a2 therapy. Clin Exp Immunol 1996;104:384-7.
20. Antonelli G, Current! M, Turriziani O, Dianzani F. Neutralising antibodies to Interferon-a: relative frequency in patients treated with different interferon preparations. J Infect Dis 1991;163:882-5.
21. Castilla A, Camps-Bansel J, Civiera M-P, Prieto J. Lymphoblastoid alpha-interferon for chronic hepatitis C: a randomised controlled study. Am J Gastroenterol 1993;88:233-9.
22. Camps J, Castilla A, Ruiz J, Civiera M, Prieto J. Randomised trial of lymphoblastoid alpha interferon in chronic hepatitis C. J Hepatol 1993; 17:390-6.
23. Bellati G, Roffi L, Antonelli G, Colloredo G, Current! M, Bellobuono A, et al. Breakthrough during therapy with natural interferon alfa for chronic hepatitis C. Hepatology 1995;22,pt2:l 14A.
24. Benutzen K, Svenson N, Jonsson V, Hippe E. Autoantibodies to cytokines. Friends or foes? Immunol Today 1990;! 1:167-9.
25. Finter NB. Why are there so many subtypes of alfa-interferon? J InterferRes 1991;(special issue) January: 185-94.
26. Rosemblum MG, Unger BW, Gutterman JU, Hersh EM, David GS, Frincke JM. Modification of human leukocyte interferon pharmacology with monoclonal antibody. Cancer Res 1985;45:2421-4.
27. Rosemblum MG, Maxwell BL, Talpaz M, Kelleher PJ, McCredie KB, Gutterman JU. In vivo sensitivity and resistance of chronic myelogenous leukemia cells to alpha-interferon: correlation with receptor binding and induction of 2',5-oligoadenylate synthetase. Cancer Res 1986;46:4848-52.
28. Billard C, Sigaux F, Castaigne S, Valensi F, Flandrin G, Degos L, et al. Treatment of hairy cell leukemia with recombinant alpha Interferon: II. In vivo down-regulation of alpha interferon receptors on tumour cells. Blood 1986;67:821-6.
29. Nakajima S, Kuroki T, Shintani M, Kurai O, Tekada T, Nishiguchi S, et al. Changes in interferon receptors on peripheral blood mononuclear cell from patients with chronic hepatitis B being treated with interferon. Hepatology 1990;12:1261-5.
30. Mariano M, Donnelly RJ, Soh J, Pestka S. Structure and function of the type 1 interferon receptor. In Interferon: Principles and medical application. Baron S, Coppenhaver DH, Dianzani F, Fleischmann WR, Hughes TK, Klimpel GR, Niesel DW, Stanton GJ, Tyring SK, editors, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA, 1992; p. 129-38.
31. Enomoto N, Sato C, Kurosaki M, Marumo F. Hepatitis C virus interferon treatment has the variation in the hypervariable region of envelope 2 gene. J Hepatol 1994;20:252-61.
32. Okada S-I, Akahane Y, Suzuki H, Okamoto H, Mishiro S. The de-grée of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 1992;16:619-24.
33. Kanazawa Y, Hayashi N, Mita E, Li T, Hagîwara H, Kasahara A, et al. Influence of viral quasispecies on effectiveness of Interferon therapy in chronic hepatitis C patients. Hepatology 1994;20:1121-30.
34. Pawlotsky JM, Bouvier M, Bastie A, Pellerin M, Dhumeaux D. Interferon alfa disrupt the equilibrium of HCV infections and alter the composition of HCV quasispecies. J Hepatol 1997;26,1S:84A.
35. Roffi L, Colloredo G, Brugnetti B, Bellati G, Ricci A, Scalori A, et al. HCV genotype and Breakthrough in patients treated with recombinant alpha interferon. Am J Gastroenterol 1998, in press.
36. Yokoyama K, Shoji S, Makita A, Hosoi H, Miyamoto N, Wakashima M, et al. Successful interferon treatment for chronic hepatitis C patients who have neutralising antibody to interferon alfa-2a. VHP ISVHLD, Tokyo 1993, p. 232, Abstract 588.
37. Negro F, Baldi M, Mondardini A, Leandro G, Chaneac M, Manzini P, et al. Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2. Gastroenterology 1994; 107:479-85.